{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["63(1)"],"submitter":["Pett SL"],"funding":["ViiV Healthcare and Pfizer Ltd","The Kirby Institute"],"pubmed_abstract":["<h4>Background</h4>Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.<h4>Methods</h4>The Maraviroc Switch Study is a randomized, multicenter, 96-week, open-label switch study in HIV type 1-infected adults with R5-tropic virus, virologically suppressed on a ritonavir-boosted protease inhibitor (PI/r) plus double nucleoside/nucleotide reverse transcriptase inhibitor (2 N(t)RTI) backbone. Participants were randomized 1:2:2 to current combination antiretroviral therapy (control), "],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pagination":["122-32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5853584"],"repository":["biostudies-literature"],"pubmed_title":["Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study."],"pmcid":["PMC5853584"],"pubmed_authors":["Pett S","Sirivichayakul S","Wadham S","Maek-A-Nantawat W","Targa M","Cuprasitrut T","Assam D","Paredes R","Belloso W","Sandhu R","Gonzalez L","Montes de Oca M","Luebke N","Taylor J","Donohue W","Gutierrez M","Delgado-Fernandez M","Chibo D","Stephan C","Rahal I","Prazuck T","Ebeling F","Walker S","Fisher M","Gibson A","Tabrett C","Porteiro N","Luchetti P","Simelane S","Land S","Baumgarten A","Puig J","Elliot J","Spath B","Stein J","Birch C","Maraviroc Switch (MARCH) Study Group","Vieni I","Lopez M","Schuelter E","Rismanto N","Imamura J","Corr S","Iwatani Y","Mejia R","Stoll M","Horban A","Berg T","Bissio E","Jaisomkom P","Vincent T","Ramon Arribas J","Drummond F","Intasan J","Beleta H","Warzywoda E","Murray S","Winston A","Murray T","Thompson J","DeJesus E","Gill J","Gonzalez-Cordon A","Zedlack C","Beider R","Tu E","Jessen H","Sanz-Moreno J","Wolff M","Ruxrungtham K","Gambardella L","Sierra Madero J","Sanchez Hernandez JE","Woolley I","Sugiura W","Hagenauer M","Sowden D","Rivas I","Silk D","Coughlan S","Reko T","Meyer-Olson D","Wolfgang J","Rockstroh J","Suzuki K","Leen C","Sierra-Madero J","Rubio AE","Morris S","Lopez Aldeguer J","Fsadni B","Avila S","Valdovinos M","Ghavami-Kia B","Yeung J","Del Moral Ponce S","Halpenny R","Italiano H","Mallon P","Marks K","Thomas Baumgarten E","Losso M","Tanabe K","Sinn K","Dean J","Naphassanant M","Barbour L","Emery S","Lefevre E","Robson R","Clark A","Rowling D","Sanchez M","Warley E","Chan W","Sinclair B","Stewart N","Fox J","Domingo P","Berthon-Jones N","Courtney-Vega K","Salomon H","Latch N","Walmsley S","Charoenporn W","Johnston C","Ponce D","Chan D","Arnaiz J","Ingiliz P","Peroni L","Jaime Ruiz Ballesteros E","Ozturk S","Merlin K","Garsia R","Leal Noval M","Kaye S","Absar N","Obermeier M","MacRae K","Amin J","Behrendt D","Kelleher A","Satyajit D","Orth D","Richardson C","Haskelberg H","Kaiser R","Arnaiz JA","Kelley M","Assmann J","Youds D","Ramos N","Sierra Aragon S","Lanteigne F","Engelhardt A","Gatell J","Hoeper K","Zarate A","Bryant M","Reyes Teran G","Callau P","Mosqueda L","Clarke A","Hehir J","Viloria G","Kok J","Pulik P","Robinette Hills J","Faetkenheur G","Feind C","Mendoza A","Madden T","Mullaney S","Guber S","Dwyer D","Ubolyam S","Imahashi M","De Paz Sierra M","Beckthold B","Nienkarken T","Franic T","Rockstroh JK","Turnham G","Pruksakaew K","Laurent Hocqueloux F","Donaldson A","Espinosa N","Mayer G","Lupo S","Gillies A","Mouawad R","King P","Haubrich R","Wienbreyer A","Miguel Castro J","Parlante A","Guelman D","Swenson L","Ignatowska A","Bloch M","Pett SL","Smith G","Vilas C","Boesecke C","Jayewardene A","Grant C","Ole Jensen BE","Cooper D","Perry N","Bakowska E","LeBlanc R","Avihingsanon A","Harrigan R","Yokomaku Y","Cuellar Tovar S","Tucker J","Andrade-Villanueva J"],"additional_accession":[]},"is_claimable":false,"name":"Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.","description":"<h4>Background</h4>Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.<h4>Methods</h4>The Maraviroc Switch Study is a randomized, multicenter, 96-week, open-label switch study in HIV type 1-infected adults with R5-tropic virus, virologically suppressed on a ritonavir-boosted protease inhibitor (PI/r) plus double nucleoside/nucleotide reverse transcriptase inhibitor (2 N(t)RTI) backbone. Participants were randomized 1:2:2 to current combination antiretroviral therapy (control), ","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jul","modification":"2025-04-18T11:49:27.167Z","creation":"2019-06-06T19:08:14Z"},"accession":"S-EPMC5853584","cross_references":{"pubmed":["27048747"],"doi":["10.1093/cid/ciw207"]}}